Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04876300
Status:
COMPLETED
Last Update Posted:
2022-01-25
First Post:
2021-05-03
Brief Title:
MEDAM Menopur Retrospective Data prograM
Sponsor:
Ferring Pharmaceuticals
Organization:
Ferring Pharmaceuticals
Study Overview
Official Title:
Predicting the Cumulative Live Birth Rate Further Ovarian Stimulation by Highly Purified Human Menotropin HP-hMG A Multicentre Retrospective Study
Status:
COMPLETED
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MEDAM
Brief Summary:
French non-interventional retrospective multicentric analysis of patients who have undergone a controlled ovarian stimulation COS for in-vitro fertilization IVF intracytoplasmic sperm injection ICSI The main objective is to determine the cumulative live birth rate with highly purified menotropin HP-hMG which is defined as the occurrence of live birth per started COS further to transfer of fresh and frozen embryos generated from the same COS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None